Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Adaptive Radiotherapy Using Plan Selection for Bladder Cancer (plan selection)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01762527
Recruitment Status : Unknown
Verified December 2015 by University of Aarhus.
Recruitment status was:  Active, not recruiting
First Posted : January 7, 2013
Last Update Posted : May 23, 2016
Sponsor:
Collaborators:
Copenhagen University Hospital at Herlev
Odense University Hospital
Information provided by (Responsible Party):
University of Aarhus

Brief Summary:
This protocol describes a Phase 2 clinical trial of online adaptive Radiotherapy, using a library of 3 dose plans corresponding to Small, Medium and Large size bladder. The procedure includes 'Common Toxicity Criteria for Adverse Effects'(CTCAE) for registration of adverse effects (baseline, every 2'nd week during RT, 2 weeks, 3, 6, 12 and 24 month after RT) as well as cineMR for intra-fractional motion (baseline and every week during RT). Patients receive standard non-adaptive RT in the first week. Delineations of the bladder on the Cone-Beam scans (CBCT) from first week of treatment are used for planning the Small and Medium size bladder plans. Large size plan are the standard non-adaptive treatment plan used for the first week of treatment. A margin of 5 mm for intra fractional movement is used.

Condition or disease Intervention/treatment Phase
Adverse Effects for Adaptive RT of Bladder Cancer Radiation: Adaptive Radiotherapy Phase 2

Detailed Description:
After inclusion patients are asked about their adverse effects by an oncologist using CTCAE (version 4.0) questionnaire. A planning CT-scan is acquired and for the first 10 patients also a MR-scan for intra fractional motion is acquired. The MR sequence is repeated every week during radiotherapy. The first week of treatment a standard non-adaptive IMRT-plan is used and CBCT-scans are acquired before and after treatment. The CBCT-scans are used for delineation of the bladder on the CBCT-scans from the first 4 fractions. The adaptive plans are generated from the union of the first 4 CBCT-bladders and the planning CT bladder (medium size) and the volume contained in at least 2 out of the 5 bladder volumes (small size). Details can be found in the reference list. From the 6'Th fraction the treatment is performed using the most appropriate size of treatment plan. CTCAE is repeated every other week during radiotherapy and 2 weeks, 3, 6, 12 and 24 month after radiotherapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 65 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Adaptive Radiotherapy Using Plan Selection for Bladder Cancer: A Phase II Trial
Study Start Date : October 2012
Estimated Primary Completion Date : October 2016
Estimated Study Completion Date : March 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bladder Cancer

Arm Intervention/treatment
Experimental: ART
Online adaptive radiotherapy
Radiation: Adaptive Radiotherapy
CTCAE scoring baseline, every 2'nd week during RT, 2 weeks, 3, 12 and 24 month after RT cineMR (time resolved MR) baseline and weekly during RT for intra fractional motion
Other Name: Online Adaptive RT using plan selection




Primary Outcome Measures :
  1. Gastro- Intestinal toxicity [ Time Frame: Up to 2 years after ART ]
    Grade 2 or more GI toxicity using CTCAE 4.0 baseline, every 2'nd week during RT, 2 weeks, 3, 12 and 24 month after RT


Secondary Outcome Measures :
  1. Intra-fractional changes of bladder shape and size [ Time Frame: spring 2013 ]
    CineMR (time resolved MR) is performed pre-treatment and weekly during RT for the first 10 patients

  2. Difference in accumulated dose to normal tissue [ Time Frame: autum 2014 ]
    The gain of normal tissue sparring will be calculated using dose accumulation

  3. 1 or 2 years disease free survival [ Time Frame: 2015 ]
    1 or 2 years disease free survival will be calculated



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically proven bladder cancer
  • Age over 18 years
  • Urothelial or planocellular carcinoma
  • Stage T2 T4A
  • Stage N0M0
  • Suitable for radiotherapy
  • ECOG/WHO performance status 0-2

Exclusion Criteria:

  • Suspected or confirmed distant metastases
  • Previous surgery in the small pelvis
  • Inflammatory bowel disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01762527


Locations
Layout table for location information
Denmark
Department of Oncology, Aarhus University Hospital
Aarhus, Denmark, 8000 C
Herlev Hospital
Herlev, Denmark, 2730
Odense University Hospital
Odense, Denmark, 5000
Sponsors and Collaborators
University of Aarhus
Copenhagen University Hospital at Herlev
Odense University Hospital
Investigators
Layout table for investigator information
Principal Investigator: Morten Høyer, MD, Professor Aarhus University Hospital

Additional Information:
Publications of Results:
Other Publications:
Layout table for additonal information
Responsible Party: University of Aarhus
ClinicalTrials.gov Identifier: NCT01762527    
Other Study ID Numbers: AUH-KFE-1217
jr.nr. 1-16-02-283-12 ( Other Grant/Funding Number: The Danish National Committee on Health Research Ethics )
First Posted: January 7, 2013    Key Record Dates
Last Update Posted: May 23, 2016
Last Verified: December 2015
Keywords provided by University of Aarhus:
Adaptive radiotherapy
Bladder cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Urinary Bladder Diseases
Urologic Diseases